Abstract
Nuclear phosphoinositide-phospholipase C (PI-PLC) beta1 plays a crucial role in the molecular steps that regulate cell proliferation and differentiation in several experimental models, such as myoblasts and hematopoietic cells, via interaction with other important molecular players. Indeed, PI-PLCbeta1 and its related molecules are definitely involved in hematopoiesis, and particularly in drug-induced myeloid or erythroid differentiation. Here, we review the role of nuclear PI-PLCbeta1 signalling in normal hematopoiesis, in pathogenesis and in drug-related induction of hematopoietic differentiation, with particular reference to the current therapy of Myelodysplastic Syndromes (MDS).
Keywords: PI-PLCbeta1, Nucleus, Cell Cycle, Differentiation, Hematopoiesis, MDS.
Current Pharmaceutical Design
Title:Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation
Volume: 22 Issue: 16
Author(s): Sara Mongiorgi, Matilde Y. Follo, Yong Ryoul Yang, Stefano Ratti, Lucia Manzoli, James A. McCubrey, Anna Maria Billi, Pann-Ghill Suh and Lucio Cocco
Affiliation:
Keywords: PI-PLCbeta1, Nucleus, Cell Cycle, Differentiation, Hematopoiesis, MDS.
Abstract: Nuclear phosphoinositide-phospholipase C (PI-PLC) beta1 plays a crucial role in the molecular steps that regulate cell proliferation and differentiation in several experimental models, such as myoblasts and hematopoietic cells, via interaction with other important molecular players. Indeed, PI-PLCbeta1 and its related molecules are definitely involved in hematopoiesis, and particularly in drug-induced myeloid or erythroid differentiation. Here, we review the role of nuclear PI-PLCbeta1 signalling in normal hematopoiesis, in pathogenesis and in drug-related induction of hematopoietic differentiation, with particular reference to the current therapy of Myelodysplastic Syndromes (MDS).
Export Options
About this article
Cite this article as:
Mongiorgi Sara, Y. Follo Matilde, Ryoul Yang Yong, Ratti Stefano, Manzoli Lucia, A. McCubrey James, Maria Billi Anna, Suh Pann-Ghill and Cocco Lucio, Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation, Current Pharmaceutical Design 2016; 22 (16) . https://dx.doi.org/10.2174/1381612822666160226132338
DOI https://dx.doi.org/10.2174/1381612822666160226132338 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Seek and Destroy: The Use of Natural Compounds for Targeting the Molecular Roots of Cancer
Current Drug Targets A New Era of Immunotherapy in Prostate Cancer
Current Molecular Pharmacology In-Silico Analysis of rSNPs in miRNA:mRNA Duplex Involved in Insulin Signaling Genes Shows a Possible Pathogenesis of Insulin Resistance
MicroRNA Anthracyclines-Contra Cruciform Extrusion in DNA Regulating Sequences
Endocrine, Metabolic & Immune Disorders - Drug Targets MiRNA-29: A microRNA Family with Tumor-Suppressing and Immune-Modulating Properties
Current Molecular Medicine Drug Targets from Genetics: Alpha-Synuclein
CNS & Neurological Disorders - Drug Targets Major Challenges for Gene Therapy of Thalassemia and Sickle Cell Disease
Current Gene Therapy Evaluating Intestinal Permeability by Measuring Plasma Endotoxin and Diamine Oxidase in Children with Acute Lymphoblastic Leukemia Treated with High-dose Methotrexate
Anti-Cancer Agents in Medicinal Chemistry Vitamin D and Cancer Mortality: Systematic Review of Prospective Epidemiological Studies
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Oncological Submissions of Dendrimer
Current Pharmaceutical Design K-Ras, Intestinal Homeostasis and Colon Cancer
Current Clinical Pharmacology Editorial (microRNA Aberrations and Their Role in Supporting Hematologic Malignancies)
MicroRNA Biological Activities, Mechanisms of Action and Biomedical Prospect of the Antitumor Ether Phospholipid ET-18-OCH3 (Edelfosine), A Proapoptotic Agent in Tumor Cells
Current Drug Metabolism Study of Splicing Factor, Proline- and Glutamine-rich by Proteomic Techniques in Human Malignant and Nonmalignant Cell Lines
Protein & Peptide Letters NF-κB Down–regulation and PARP Cleavage by novel 3-α-butyryloxy-β-boswellic Acid Results in Cancer Cell Specific Apoptosis and in vivo Tumor Regression
Anti-Cancer Agents in Medicinal Chemistry KSP Inhibitors as Antimitotic Agents
Current Topics in Medicinal Chemistry Development and Clinical Application of Peptide-Based Radiopharmaceuticals
Current Pharmaceutical Design Adverse Events of Proton Pump Inhibitors: Potential Mechanisms
Current Drug Metabolism Regulation of Inflammation: A Review of Recent Advances in Anti- Inflammatory Strategies
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Recent Advances in Thymidine Kinase 2 (TK2) Inhibitors and New Perspectives for Potential Applications
Current Pharmaceutical Design